Stocks

AbbVie's Myeloma Breakthrough Fails to Dent JNJ Gains

Guavy AI Editorial Team Published September 4, 2026

Instruments

JNJ

Johnson & Johnson (JNJ) shares rose around 1% to $277.955 on Thursday afternoon, despite AbbVie's experimental multiple-myeloma drug etentamig posting impressive results in a clinical trial. The treatment achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies.

A key point is that AbbVie's success with etentamig is seen as category expansion, rather than a direct threat to J&J's Carvykti franchise. Reuters noted that etentamig currently appears most differentiated after CAR-T therapy, not as an immediate substitute for Carvykti.

J&J's second-quarter results highlighted the importance of its Innovative Medicine segment, with Carvykti being a major growth driver behind 6.8% operational growth in this area.

AbbVie's Myeloma Breakthrough Fails to Dent JNJ Gains

$200 Credit Available with American Express Ikon Pass Offer

Amex Undervalued by Market: Financials and Customer Base Outperform Peers

Miley Cyrus Returns to the Hollywood Bowl: Presale Tickets Available to Amex Members